Curis CMO converts preferred into common shares

Curis Inc. Chief Medical Officer Ahmed Hamdy converted preferred stock into common shares.

Accepted by SEC EDGAR 03/23/2026 - 04:03 PM EDT

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Curis Inc. Chief Medical Officer Ahmed Hamdy converted preferred stock into common shares. On March 20, 2026, 50 shares of Series B Convertible Preferred Stock were converted into 66,667 shares of common stock for no additional consideration, leaving no Series B Preferred outstanding for him and 66,667 common shares held directly.

Insider Trade Summary

50 shares exercised/converted

Exercise 2 txns

Insider Hamdy Ahmed MD

Role CMO

Type	Security	Shares	Price	Value
Conversion	Series B Convertible Preferred Stock	50	$0.00	$0.00
Conversion	Common Stock	66,667	$0.00	$0.00

Holdings After Transaction: Series B Convertible Preferred Stock — 0 contracts (Direct); Common Stock — 66,667 shares (Direct)

Holdings Before and After: Series B Convertible Preferred Stock, 50 to 0 contracts (Direct); Common Stock, 0 to 66,667 shares (Direct)

Footnotes (1)

F1. Each share of Series B Convertible Non-Redeemable Preferred Stock ("Series B Preferred Stock") automatically converted into 1,333.33 shares of Common Stock, for no additional consideration, at 5 p. m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Curis (CRIS) CMO Ahmed Hamdy report in this Form 4?

Ahmed Hamdy reported a conversion of preferred stock into common shares. On March 20, 2026, 50 Series B Convertible Preferred shares converted into 66,667 Curis common shares, increasing his direct common stock holdings without an open-market purchase or sale.

How many Curis common shares did the CMO receive in the latest transaction?

The CMO received 66,667 Curis common shares through a derivative conversion. These shares resulted from converting 50 shares of Series B Convertible Preferred Stock, with no cash consideration paid at conversion, and are now held directly after the transaction.

What type of security did Curis CMO Hamdy convert into common stock?

He converted Series B Convertible Non-Redeemable Preferred Stock into common stock. Each preferred share automatically converted into 1,333.33 Curis common shares, subject to the Certificate of Designations and Beneficial Ownership Limitations described for the Series B Preferred Stock.

Did the Curis CMO buy or sell shares on the open market in this Form 4?

He neither bought nor sold shares on the open market. The filing shows a derivative conversion, where 50 Series B Convertible Preferred shares automatically became 66,667 common shares for no additional consideration, changing only the form of his ownership.

How many Series B Convertible Preferred shares does the Curis CMO hold after conversion?

After the reported conversion, he holds no Series B Convertible Preferred shares. All 50 reported Series B Preferred shares converted into 66,667 Curis common shares, and his remaining reported position consists solely of these directly held common shares.

What were the original terms when the Curis Series B Preferred Stock was sold?

Each Series B Preferred share was sold as part of a "Security" unit. Each unit included one Series B Preferred share plus three series of warrants, at a purchase price of $1,000.00 per unit to Ahmed Hamdy, according to the transaction footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hamdy Ahmed MD

(Last)

(First)

(Middle)

128 SPRING STREET

BUILDING C - SUITE 500

(Street)

LEXINGTON

MASSACHUSETTS

02421

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CURIS INC [ CRIS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CMO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/20/2026		C		66,667	A	⁽¹⁾	66,667	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Series B Convertible Preferred Stock	⁽¹⁾	03/20/2026		C			50	⁽¹⁾	⁽¹⁾	Common Stock	66,667	⁽¹⁾	0	D

Explanation of Responses:

1. Each share of Series B Convertible Non-Redeemable Preferred Stock ("Series B Preferred Stock") automatically converted into 1,333.33 shares of Common Stock, for no additional consideration, at 5 p. m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person.

Remarks:

	/s/ Diantha Duvall, Attorney-in-fact	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR